The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback